Hair loss products for men are among the most searched health topics in the UK, yet navigating the options can be confusing. Male pattern hair loss — androgenetic alopecia — affects around half of men over 50, and while the market is flooded with shampoos, supplements, and serums, only a handful of treatments are backed by robust clinical evidence. This guide explains the causes of male hair loss, the NHS-recognised treatments available in the UK, how to choose the right product for your specific type of hair loss, and the safety considerations every man should understand before starting treatment.

Understanding Male Pattern Hair Loss and Its Causes

Male pattern hair loss is caused by genetic sensitivity of hair follicles to DHT, a testosterone-derived androgen, leading to progressive follicular miniaturisation. Red flags such as sudden, patchy, or scarring hair loss require GP review before any treatment is started.

Not sure if this is normal? Chat with one of our pharmacists →

Male pattern hair loss, clinically known as androgenetic alopecia, is the most common cause of hair loss in men, affecting approximately 50% of men over the age of 50 in the UK. It is characterised by a predictable pattern of recession — typically beginning at the temples or crown — and is classified using the Norwood-Hamilton scale, which ranges from minimal recession to near-complete baldness.

The primary driver of androgenetic alopecia is a sensitivity of hair follicles to dihydrotestosterone (DHT), a potent androgen derived from testosterone via the enzyme 5-alpha reductase. In genetically susceptible individuals, DHT binds to receptors in scalp follicles, causing them to miniaturise progressively. Over time, affected follicles produce thinner, shorter hairs until they eventually cease producing visible hair altogether.

Genetics plays a central role — the condition is polygenic, meaning multiple genes contribute to susceptibility, inherited from both maternal and paternal lines. However, other factors can accelerate or mimic hair loss, including:

• Nutritional deficiencies (e.g., iron deficiency or anaemia) — testing should be clinically indicated (e.g., FBC and ferritin if anaemia is suspected) rather than routine screening of multiple micronutrients

• Thyroid dysfunction (hypothyroidism or hyperthyroidism) — thyroid function tests are appropriate where symptoms or signs are present

• Chronic stress or significant physical illness (telogen effluvium), which causes diffuse shedding rather than patterned miniaturisation

• Scalp conditions such as seborrhoeic dermatitis, which may exacerbate shedding and itch but does not cause the patterned follicular miniaturisation characteristic of androgenetic alopecia

It is important to distinguish androgenetic alopecia from other forms of hair loss before selecting any treatment. Men should seek prompt GP or dermatology review if they notice any of the following red flags: sudden or rapidly progressive hair loss, patchy or irregular loss, scalp pain, tenderness, inflammation or scarring, loss involving the eyebrows or beard, or any associated systemic symptoms such as fatigue or weight change. These features may indicate conditions such as alopecia areata, scarring alopecia, or an underlying medical cause requiring investigation rather than cosmetic treatment. A GP can help identify the underlying cause through clinical examination and targeted investigations, ensuring that men pursue the most appropriate hair loss products for men rather than self-treating a potentially reversible condition.

NHS-Recognised Treatments and Hair Loss Products for Men

Topical minoxidil and oral finasteride 1 mg are the two clinically evidenced, MHRA-recognised treatments for male pattern hair loss in the UK. Finasteride is prescription-only and not routinely available on the NHS; other marketed products such as caffeine shampoos lack NICE endorsement.

In the UK, two treatments are widely recognised and supported by clinical evidence for male pattern hair loss: topical minoxidil and oral finasteride. Both are acknowledged by NICE and the MHRA as effective options, though they work through entirely different mechanisms.

Minoxidil is available over the counter as a topical solution or foam, typically in 2% or 5% concentrations. Originally developed as an antihypertensive, it was observed to stimulate hair growth as a side effect. Its precise mechanism in hair loss is not fully understood, but it is thought to prolong the anagen (growth) phase of the hair cycle, possibly via potassium channel opening and vasodilatory effects on the scalp. According to the UK-licensed product information (SmPC), the 5% solution or foam for men is generally applied twice daily to the affected area of the scalp. Consistent, long-term use is required — results are typically visible after three to six months. Men should follow the specific dosing and application instructions on the licensed product they are using.

Experiencing these side effects? Our pharmacists can help you navigate them →

Finasteride 1 mg (prescription-only) is an oral medication that works by inhibiting 5-alpha reductase, thereby reducing DHT levels in the scalp by approximately 60–70%. Clinical trials have demonstrated that finasteride slows hair loss progression and promotes regrowth in the majority of men with mild to moderate androgenetic alopecia. It must be prescribed by a GP or licensed UK prescriber. Finasteride is not routinely available on the NHS for cosmetic hair loss and is typically obtained privately through a UK-regulated prescriber or online clinic.

Other products widely marketed as hair loss treatments — including caffeine shampoos, biotin supplements, and laser combs — have limited or inconsistent clinical evidence. While some men report subjective improvement, none are currently endorsed by NICE as standalone treatments. They may be used as adjuncts but should not replace evidence-based therapies where hair loss is progressive.

When selecting any hair loss product, men should ensure it holds a UK marketing authorisation granted by the MHRA. Products should not be sourced from unregulated or overseas suppliers, as quality, safety, and authenticity cannot be guaranteed.

How to Choose the Right Product for Your Type of Hair Loss

Product choice depends on the confirmed type and severity of hair loss; combined minoxidil and finasteride is a common approach for androgenetic alopecia at Norwood grades II–V. Diffuse or sudden hair loss should be assessed by a GP before any product is purchased.

Selecting the most appropriate hair loss product depends on several factors, including the type and pattern of hair loss, its severity, the individual's medical history, and personal preference regarding treatment format. Not all hair loss responds to the same interventions, which is why accurate diagnosis is the essential first step.

For men with confirmed androgenetic alopecia at an early to moderate stage (Norwood grades II–V), using topical minoxidil alongside oral finasteride is a common clinical approach, as the two treatments target different aspects of the hair loss process. Minoxidil stimulates follicular activity, while finasteride addresses the hormonal cause. Studies suggest that combined use may produce superior results compared to either treatment alone. It is important to note that each product is licensed individually; a combined regimen should be discussed with a clinician before commencing.

For men experiencing diffuse hair thinning rather than a defined pattern, or those with sudden onset hair loss, it is advisable to consult a GP before purchasing any product. Conditions such as telogen effluvium, alopecia areata, or nutritional deficiency require different management strategies entirely — and using DHT-blocking products in these cases would be ineffective.

When evaluating hair loss products for men, consider the following practical points:

• Consistency of use — both minoxidil and finasteride require ongoing application; stopping treatment typically results in reversal of any gains within 6–12 months

• Realistic expectations — these treatments slow or halt progression and may stimulate partial regrowth, but are unlikely to fully restore a significantly receded hairline

• Regulatory status — choose only products with a UK marketing authorisation (MHRA-licensed); be cautious of unregulated supplements or imported products making exaggerated claims

• Cost and accessibility — minoxidil is widely available in pharmacies; finasteride requires a prescription and is typically obtained through private GP services or regulated UK online clinics

For men with atypical, refractory, or rapidly progressive hair loss, referral to a consultant dermatologist is appropriate. Hair transplantation is a surgical option for suitable candidates and may be considered when medical treatments have been optimised or are not appropriate. Cosmetic camouflage products (e.g., scalp concealers, hair fibres) can also provide a non-medical option for managing the appearance of thinning hair.

It is worth noting that oral dutasteride is sometimes used by specialists for androgenetic alopecia, but it does not hold a UK marketing authorisation for this indication and its use is therefore off-licence. It should only be considered under specialist supervision.

Potential Side Effects and Safety Considerations

Finasteride carries MHRA safety warnings for depression and suicidal thoughts, and men should stop treatment immediately and seek medical help if affected. Minoxidil is generally well tolerated topically, though systemic absorption can cause palpitations or hypotension.

As with all medicinal treatments, hair loss products for men carry a risk of side effects, and it is important that men are fully informed before commencing therapy.

Minoxidil is generally well tolerated when used topically. The most commonly reported side effects include:

• Scalp irritation, dryness, or flaking — often related to the propylene glycol base in solution formulations (foam preparations may be better tolerated)

• Initial shedding in the first four to eight weeks of use — this is a normal part of the hair cycle reset and typically resolves

• Unwanted facial hair growth if the product contacts the face

• Palpitations, dizziness, or hypotension — these may indicate systemic absorption and warrant discontinuation and medical advice

• Minoxidil should not be applied to broken, inflamed, or irritated skin, as this may increase systemic absorption

Finasteride 1 mg carries a more significant side effect profile that warrants careful consideration and discussion with a prescriber before starting treatment.

• A small proportion of men (estimated at 1–4% in clinical trials) report sexual side effects, including reduced libido, erectile dysfunction, and decreased ejaculatory volume. In most cases, these resolve upon discontinuation.

• The MHRA has issued safety warnings that finasteride 1 mg is associated with reports of depression and suicidal thoughts. Men taking finasteride should be advised to stop treatment immediately and seek medical help if they experience low mood, depression, or any thoughts of self-harm. Prescribers should provide patients with the MHRA patient alert card, which summarises these risks.

• There have been reports — referred to as Post-Finasteride Syndrome — of persistent sexual, neurological, and psychological symptoms following cessation of treatment. The MHRA acknowledges these reports and notes that research into a definitive causal link is ongoing. Men should discuss this risk with their prescriber before starting finasteride.

• Men should seek prompt medical review if they notice breast changes such as pain, tenderness, lumps, or nipple discharge whilst taking finasteride.

• Finasteride lowers PSA (prostate-specific antigen) levels, which may affect prostate cancer screening results — this should be disclosed to any clinician ordering PSA tests.

• Finasteride is absolutely contraindicated in women of childbearing potential due to the risk of feminisation of a male foetus. Pregnant women should not handle crushed or broken finasteride tablets, as the active ingredient can be absorbed through the skin.

Reporting side effects: Men who experience suspected side effects from any hair loss treatment are encouraged to report them via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk. This helps the MHRA monitor the ongoing safety of medicines available in the UK.

Men should seek GP advice if they experience sudden or patchy hair loss, hair loss associated with scalp pain or scarring, or any systemic symptoms such as fatigue or weight changes, as these may indicate an underlying medical condition requiring investigation rather than cosmetic treatment.

Frequently Asked Questions